In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab.

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

Sanofi agreed to buy Blueprint Medicines for up to $9.5 billion, the French drugmaker's biggest move yet to replenish its drug pipeline since it sold a controlling stake in its consumer-healthcare arm ...

Arguably the most notable of the FDA’s upcoming decisions is that regarding Gilead’s twice-yearly HIV prophylaxis lenacapavir ...

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

Additional data presented at ASCO highlights Libtayo’s ability to hold off recurrence of a type of skin cancer.

The investigational drug demonstrated robust STAT6 degradation in blood and skin that was well tolerated and safe in healthy volunteers.

Sanofi SNY announced that it has entered into a definitive agreement to acquire Blueprint Medicines BPMC for a total deal ...

Walt Disney is laying off several hundred people globally across multiple divisions, including marketing for film and television, TV publicity, casting and development, and corporate financial ...

French drugmaker adds Ayvakit and next-gen immunology pipeline in strategic move to dominate rare disease space Sanofi has ...